CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...